The Choose Medicare Act would establish a Medicare Part E that would give employers and the general public the ability to opt ...

Results show the regimen of epcoritamab plus R-ICE could serve most patients as a bridge to either autologous stem cell ...

Garadacimab-gxii is the first and only treatment that targets factor XIIa (FXIIa) for the prophylactic prevention of reditary ...

Real-world cost barriers and insurance denials contribute to early discontinuation of injectable glucagon-like peptide-1 (GLP ...

Panelists discuss potential changes to clinical pathways for Bruton tyrosine kinase (BTK) inhibitor therapies as a result of ...

Panelists discuss the specific challenges and barriers clinicians might encounter when utilizing different BTK inhibitors ...

As clinician shortages grow, hospitals turn to artificial intelligence (AI) and scheduling tools to optimize resources, ...

Andrew Evens, DO, MBA, MSc, deputy director for clinical services and chief physician officer, Rutgers Cancer Institute, introduces New Jersey's new state-of-the-art facilities at the Jack & Sheryl ...

Topical ruxolitinib cream shows promise as a treatment for inflammatory skin conditions, but lacks consistent data, indicating a need for further research into its use across various dermatologic ...

With the approval of the FDA, garadacimab can help patients with hereditary angioedema (HAE) prevent attacks by shutting down the contact pathway.

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

A panelist discusses the latest advancements presented at ASCO 2025, highlighting talquetamab’s pivotal trial in relapsed/refractory multiple myeloma that demonstrated high response rates and longer ...